Drug Discovery

As a contract research organization we provide the full range of drug discovery chemistry services and offer integrated solutions

Taros’ international and diverse team has more than 180 years of pharmaceutical R&D experience. Collectively as a team, we worked on more than 120 biomolecular targets from all major gene families and across all main therapeutic areas. As a privately owned Contract Research Organization we are running our own state-of-the-art Drug Discovery Chemistry facilities with the option for:

  • Medicinal chemistry from hit validation to candidate selection
  • Computational chemistry and molecular modeling
  • Compound library design and production
  • Parallel chemistry for high throughput experimentation
  • Route scouting, process development and scale up to pilot plant
  • Partners for outsourcing disease biology, HTS, ADME, DMPK, X-ray crystallography
design and synthesis of peptide and peptidomimetics within medicinal chemistry research

Medicinal Chemistry

In Medicinal Chemistry research, we are working with a broadly experienced team on all biomolecular targets from any gene family in any therapeutic area. Our expertise…

Taros computational chemistry expertise encompasses the whole spectrum of computer-aided drug design, from virtual screening to adaptive SAR analysis as well as molecular modelling to statistical forecasting.

Computational Chemistry and Molecular Modeling

We routinely apply computer sciences in computational chemistry approaches and apply methods for structure-based drug design, in case structural data of the target…

Parallel chemistry and combinatorial chemistry for compound libraries and high throughput experimentation

Parallel Chemistry and Compound Libraries

High quality library design requires chemical creativity and profound synthesis knowledge to achieve the highest possible molecular diversity. Our efficient production…

Biotech Corporations

Biotechs simply concentrate on their research and development tasks while our experienced chemists take care of all related synthetic chemistry challenges.

Pharmaceutical Industry

Providing hihgly innovative but cost efficient early drug discovery services and technologies to our pharma customers is what drives our multidisciplinary scientists at Taros.

Research Institutes and Academia

Great academic research often requires industrial backing and excellent synthesis capacities to bring ideas to the market – for many years we have been closing that gap.

Reaction Calorimetry

Process development

  • We are transforming your ideas into products
  • From early discoveries and R&D chemistry in the laboratory to pilot scale for your application testing
  • Always considering economic and safety boundaries and conditions laid out for all stages of the project

Pilot plant manufacturing

  • We are running our own state-of-the-art pilot plant facility
    in Asia with access to a broad supplier network
  • Providing samples of your compounds and specialties
    in pilot scale for your extended application testing
  • Large-scale synthesis and custom manufacturing opportunities
Reaction vessels for custom manufacturing of chemicals
HPLC

Analytical chemistry and
purification

  • Providing analytical services and quality control for your purpose
  • Several spectroscopic methods available including NMR,FT-IR,UV/VIS, etc.
  • Calorimetric methods to monitor reactions and processes at every of the project
Looking for

integrated drug discovery services?

Bioscience includes serveral approaches of assay development and in vivo pharmacology within the drug discovery process
Drug metabolism and pharmacokinetics and Absorption, Distribution, Metabolism, Excretion data are essential within the lead optimization phase to develop clinical candidates
Performing synthetic chemistry and medicinal chemistry to yield novel organic compounds with druglike physicochemical properties

Committed to customers and success, we use all drug discovery approaches

We are exploring entry points into drug discovery and medicinal chemistry projects in an unbiased manner. High-throughput screening (HTS) and focused screening yields typically good quality hits through additional counter screens to ensure hit validation. This approach allows for the highest level of serendipity. Our molecular design capabilities are following both, structure- and ligand-based designs, as well as peptidomimetic techniques. Chemogenomics and fragment-based screening focuses on phylogenetic trees and good experience has been made across gene families when binding sites have been preserved. Selecting starting points from literature or IP knowledge yields traditionally high success rates with a shorter path to proof of concept (PoC) in animal models.

  • Rational molecular design techniques like structure- and ligand-based designs as well as peptidomimetic approaches
  • Literature and patent-inspired approaches which traditionally ensure a high success rate as well as a short track to POC in disease models
  • High-throughput screening (HTS), medium throughput screening (MTS) as well as focused screening provide high quality hits and allows serendipity
  • Fragment-based lead generation may uncover multiple binding sites and induce transient binding pockets
  • Target family approaches, respectively Chemogenomics to focus on phylogenetic trees, GPCR SST5 as a quite good example